News
Does the emergence of resistance to cetuximab mean ineffectiveness of all anti-EGFR antibodies?
Colorectal cancer (CRC) cells respond to targeted therapy in different ways. Besides the desired outcome of cell death, CRC cells can adapt and survive through changes in their genome. It is important to recognize that the developed resistance to targeted therapy may, but does not necessarily, apply uniformly across a class of drugs or a single mechanism of action.
VIDEO: Antibiotic Treatment of Infections Caused by MDR Bacteria – Seminar Recording
Recording of a professional seminar on the topic of infections caused by MDR bacteria, which took place...
Genetic Profiling Transforms the Diagnosis and Treatment of Cancer Diseases
Genome sequencing provides doctors with more information about the causes of cancer diseases and…
Dosing of Enoxaparin in Morbidly Obese Patients
How to optimally dose enoxaparin in morbidly obese patients? This question was addressed by a…
Is long-term treatment with ixekizumab sufficiently safe?
Psoriasis is a chronic inflammatory disease whose manifestations require long-term treatment. A…
Do Asthma Bronchiale and COPD Represent a Risk Factor for Severe COVID-19 and Death?
It is well known that patients with bronchial asthma and chronic obstructive pulmonary disease…
Risk Factors for Renal Cancer Formation After Kidney Transplantation
German authors in the below-cited work identified modifiable risk factors associated with the…
Kidney Carcinoma – Key Facts About the Disease With the Highest Incidence Worldwide in the Czech Republic
The incidence of renal carcinoma is increasing every year. About a quarter of the cases are still…
Clinical Characteristics of Trauma Patients Requiring Dosing Adjustments of Enoxaparin in TEN Prevention
Injuries and trauma surgical procedures represent a significant risk factor for the development of…
Cost-Effectiveness of Preparations Used to Stop Bleeding in Patients with AHA
Choosing the right preparation to manage acute bleeding in patients with acquired hemophilia A is…